Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection

World Health Organization. Coronavirus (COVID-19). Accessed 14 Jun 2020. Available from: https://covid19.who.int/. Siddiqi, 2020, COVID-19 illness in native and immunosuppressed states: A clinical–therapeutic staging proposal, J Heart Lung Transplant., 39, 405, 10.1016/j.healun.2020.03.012 Chu, 2004, Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings, Thorax., 59, 252, 10.1136/thorax.2003.012658 Cao, 2020, A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19, N Engl J Med., 382, 1787, 10.1056/NEJMoa2001282 Kang, 2015, Intravenous tacrolimus and cyclosporine induced anaphylaxis: what is next?, Asia Pac Allergy., 5, 181, 10.5415/apallergy.2015.5.3.181 Manfredi, 2007, Clinical Ritonavir and Lopinavir Hypersensitivity Confirmed by a Specific In Vitro Cellular Allergen Stimulation Test, Curr HIV Res., 5, 440, 10.2174/157016207781023956 Sheahan, 2020, Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV, Nat Commun., 11, 222, 10.1038/s41467-019-13940-6 Grein, 2020, Compassionate Use of Remdesivir for Patients with Severe Covid-19, N Engl J Med., 382, 2327, 10.1056/NEJMoa2007016 Wang, 2020, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, Lancet., 395, 1569, 10.1016/S0140-6736(20)31022-9 Registro Español de Ensayos Clínicos. Agencia Española de Medicamentos y Productos Sanitarios. Número EudraCT 2020-000842-32. Consultado el 21/04/2020, https://reec.aemps.es/reec/public/web.html. Agencia Española de medicamentos y productos sanitarios (AEMPS). Tratamientos disponibles para el manejo de la infección respiratoria por SARS-CoV-2. Consultado el 23 de abril de 2020, https://www.aemps.gob.es/la-aemps/ultima-informacion-de-la-aemps-acerca-del-covid‑19/tratamientos-disponibles-para-el-manejo-de-la-infeccion-respiratoria-por-sars-cov-2/. Ferner, 2020, Chloroquine and hydroxychloroquine in covid-19, BMJ, 369, m1432, 10.1136/bmj.m1432 Guastalegname, 2020, Could chloroquine /hydroxychloroquine be harmful in Coronavirus Disease 2019 (COVID-19) treatment?, Clin Infect Dis., ciaa321 Akpovwa, 2016, Chloroquine could be used for the treatment of filoviral infections and other viral infections that emerge or emerged from viruses requiring an acidic pH for infectivity, Cell Biochem Funct., 34, 191, 10.1002/cbf.3182 Agencia Española de medicamentós y productos sanitarios (AEMPS). Cloroquina/Hidroxicloroquina: precauciones y vigilancia de posibles reacciones adversas en pacientes con COVID-19. Nota de seguridad 22 abril. Available from: https://www.aemps.gob.es/informa. 2020, Some Drugs Being Considered for Treatment of COVID-19 Repurposed Drugs, The Medical Letter on Drugs and Therapeutics., 19 Riley, 2019, Assessment of Antimalarial Therapy in Patients Who Are Hypersensitive to Hydroxychloroquine, JAMA Dermatology., 155, 491, 10.1001/jamadermatol.2018.5212 LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK547852/. Bethesda (MD); 2012. Girijala, 2019, Pustular DRESS Syndrome Secondary to Hydroxychloroquine With EBV Reactivation, J Drugs Dermatol., 18, 207 Donado, 2010, Successful Desensitization for Hydroxychloroquine Anaphylaxis, J Rheumatol., 37, 1975, 10.3899/jrheum.091453 Caly, 2020, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res., 178, 10.1016/j.antiviral.2020.104787 Ivermectin side effects. Drugs.com. Disponible en https://www.drugs.com/sfx/ivermectin-side-effects.html. Consultado el 13/04/20. Seegobin, 2018, Toxic epidermal necrolysis after ivermectin, Am J Emerg Med., 36, 887, 10.1016/j.ajem.2017.09.021 Aroke, 2017, Ivermectin induced Steven–Johnsons syndrome: case report, BMC Res Notes., 10, 179, 10.1186/s13104-017-2500-5 Ohe, 2020, Macrolide treatment for COVID-19: Will this be the way forward?, Biosci Trends., 14, 159, 10.5582/bst.2020.03058 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents., 10.1016/j.ijantimicag.2020.105949 Garcia-Cremades, 2020, Optimizing Hydroxychloroquine Dosing for Patients With COVID-19: An Integrative Modeling Approach for Effective Drug Repurposing [published online ahead of print, 2020 Apr 14], Clin Pharmacol Ther. Barni, 2015, Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides, J Investig Allergol Clin Immunol., 25, 128 Blumenthal, 2019, Antibiotic allergy, Lancet., 393, 183, 10.1016/S0140-6736(18)32218-9 Sánchez-Borges, 2013, Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy, World Allergy Organ J., 6, 18, 10.1186/1939-4551-6-18 Channappanavar, 2017, Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology, Semin Immunopathol., 39, 529, 10.1007/s00281-017-0629-x Fu, 2020, Why tocilizumab could be an effective treatment for severe COVID-19?, J Transl Med., 18, 164, 10.1186/s12967-020-02339-3 Cortellini, 2018, Effective Desensitization to Tocilizumab in Delayed Hypersensitivity Reaction, Pharmacology., 114, 10.1159/000490419 Park, 2020, Tocilizumab-induced anaphylaxis in patients with adult-onset Still’s disease and systemic juvenile idiopathic arthritis: a case-based review, Rheumatol Int., 40, 791, 10.1007/s00296-019-04456-9 Lu, 2020, Potential therapeutic agents against COVID-19: What we know so far, J Chin Med Assoc., 83, 534, 10.1097/JCMA.0000000000000318 Lau, 2013, Delayed induction of proinflammatory cytokines and suppression of innate antiviral response by the novel Middle East respiratory syndrome coronavirus: implicpyations for pathogenesis and treatment, J Gen Virol., 94, 2679, 10.1099/vir.0.055533-0 Richardson, 2020, Baricitinib as potential treatment for 2019-nCoV acute respiratory disease, Lancet., 395, e30, 10.1016/S0140-6736(20)30304-4 Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet., 395, 565, 10.1016/S0140-6736(20)30251-8 Sorrell, 2016, Family-wide Structural Analysis of Human Numb-Associated Protein Kinases, Structure., 24, 401, 10.1016/j.str.2015.12.015 Mogul, 2019, Baricitinib: The Second FDA-Approved JAK Inhibitor for the Treatment of Rheumatoid Arthritis, Ann Pharmacother., 53, 947, 10.1177/1060028019839650 Kaiser, 2012, Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations, Rheumatol Int., 32, 295, 10.1007/s00296-011-2096-3 Dinarello, 2011, Interleukin-1 in the pathogenesis and treatment of inflammatory diseases, Blood., 117, 3720, 10.1182/blood-2010-07-273417 Alpay, 2012, Efficacy of anakinra treatment in a patient with colchicine-resistant familial Mediterranean fever, Rheumatol Int., 32, 3277, 10.1007/s00296-010-1474-6 Ramírez, 2018, Anakinra for the treatment of rheumatoid arthritis: a safety evaluation, Expert Opin Drug Saf., 17, 727, 10.1080/14740338.2018.1486819 YIlmaz, 2017, Successful rapid subcutaneous desensitization to anakinra in a case with a severe immediate-type hypersensitivity reaction, Eur Ann Allergy Clin Immunol, 50, 94, 10.23822/EurAnnACI.1764-1489.30 Desai, 2009, Anaphylactic Reaction to Anakinra in a Rheumatoid Arthritis Patient Intolerant to Multiple Nonbiologic and Biologic Disease-Modifying Antirheumatic Drugs, Ann Pharmacother., 43, 967, 10.1345/aph.1L573 Soyyiğit, 2014, Successful desensitization with anakinra in a case with immediate hypersensitivity reaction, Ann Allergy, Asthma Immunol., 113, 325, 10.1016/j.anai.2014.06.017 Kalt, 2017, Tacrolimus: A Review of Laboratory Detection Methods and Indications for Use, Lab Med., 48, e62, 10.1093/labmed/lmx056 Shi, 2020, COVID-19 infection: the perspectives on immune responses, Cell Death Differ., 27, 1451, 10.1038/s41418-020-0530-3 Mehta, 2020, COVID-19: consider cytokine storm syndromes and immunosuppression, Lancet, 395, 1033, 10.1016/S0140-6736(20)30628-0 Ponticelli, 2019, Prevention of complications from use of conventional immunosuppressants: a critical review, J Nephrol., 32, 851, 10.1007/s40620-019-00602-5 Riley, 2000, Cross-sensitivity reaction between tacrolimus and macrolide antibiotics, Bone Marrow Transplant., 25, 907, 10.1038/sj.bmt.1702223 Li, 2018, Effect of interferon alpha and cyclosporine treatment separately and in combination on Middle East Respiratory Syndrome Coronavirus (MERS-CoV) replication in a human in-vitro and ex-vivo culture model, Antiviral Res., 155, 89, 10.1016/j.antiviral.2018.05.007 Sumpton, 2001, Hypersensitivity to cyclosporine (Neoral) and successful desensitization, Transplant Proc., 33, 3015, 10.1016/S0041-1345(01)02289-8 WHO. Clinical management of severe acute respiratory infection when COVID-19 is suspected (v1.2). 2020;1-21. Available from: https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected. https://www.recoverytrial.net/news/low-cost-dexamethasone-reduces-death-by-up-to-one-third-in-hospitalised-patients-with-severe-respiratory-complications-of-covid-19. Pedrós, 2014, Prevalence, risk factors and main features of adverse drug reactions leading to hospital admission, Eur J Clin Pharmacol., 70, 361, 10.1007/s00228-013-1630-5